Actavis Specialty Brands, formerly known as the Global Brands business, markets more than 40 brand pharmaceutical products, primarily in the U.S.
The division is focused on leadership in Urology and Women’s Health. Internationally, we are also expanding our Actavis Specialty Brands business in Canada and Latin America, and pursuing opportunities to expand in other key markets.
The Company is also pursuing a strategy to build a leadership position in biosimilars, which includes a collaboration with Amgen to develop and commercialize,on a worldwide basis, biosimilar versions of Herceptin®, Avastin®, Rituxan/Mab Thera®, and Erbitux®. These products represent some of the fastest-growing pharmaceutical products in the world with peak innovator sales topping $20 billion, and we expect the collaboration to launch its first biosimilar products beginning in 2017.
The Amgen/Actavis collaboration is in addition to Actavis’ ongoing efforts to develop and commercialize Itero Biopharmaceuticals, Inc.’s recombinant follicle stimulating hormone (rFSH) product as a biosimilar molecule for the treatment of female infertility. The program is currently in Phase I and the Company expects it to progress to Phase III in 2013.